IBB vs VXX
iShares Biotechnology ETF vs iPath Series B S&P 500 VIX Short-Term Futures ETN
IBB$196.62
iShares Biotechnology ETF
NASDAQ biotech and pharmaceutical companies.
Expense: 0.44%Yield: 0.22%
VXX$21.66
iPath Series B S&P 500 VIX Short-Term Futures ETN
VIX short-term futures, hedge / speculation.
Expense: 0.89%Yield: 0.00%
Quick take
- • IBB has the lower expense ratio at 0.44% vs 0.89% for VXX.
- • IBB pays a higher dividend yield (0.22%).
Side-by-side metrics
| Metric | IBB | VXX |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.44% | 0.89% |
Dividend yield Trailing 12-month yield. | 0.22% | 0.00% |
AUM Assets under management — bigger funds are typically more liquid. | $9.09B | $441M |
YTD return | 16.44% | -16.85% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 0.69 | 45.83 |
P/E ratio | 24.79 | — |
Last price | $196.62 | $21.66 |
Inception | — | — |
Issuer | iShares | Barclays |
IBB top holdings
Top holdings · IBB
| VRTX | Vertex Pharmaceuticals Inc | 8.07% |
| AMGN | Amgen Inc | 7.82% |
| GILD | Gilead Sciences Inc | 6.83% |
| REGN | Regeneron Pharmaceuticals Inc | 4.90% |
| ARGX | argenx SE ADR | 3.75% |
| ALNY | Alnylam Pharmaceuticals Inc | 3.12% |
| NTRA | Natera Inc | 2.89% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 2.78% |
| BIIB | Biogen Inc | 2.46% |
| ILMN | Illumina Inc | 2.07% |
Sector breakdown · IBB
Healthcare100.0%
VXX top holdings
Holdings data unavailable for VXX.
About IBB
IBB (iShares Biotechnology ETF) is NASDAQ biotech and pharmaceutical companies. Managed by iShares, the fund carries $9.1B in assets under management, an expense ratio of 0.44%, a dividend yield of 0.22%. Its largest holding is Vertex Pharmaceuticals Inc (VRTX), which represents 8.1% of the portfolio. Healthcare is the fund's largest sector exposure at 100.0%.
About VXX
VXX (iPath Series B S&P 500 VIX Short-Term Futures ETN) is VIX short-term futures, hedge / speculation. Managed by Barclays, the fund carries $441M in assets under management, an expense ratio of 0.89%.